Citation

Pop G, Farcaș A, Butucă A, Morgovan C, Arseniu AM, Pumnea M, Teodoru M, Gligor FG. Pharmaceuticals (Basel) 2022; 15(12).

Copyright

(Copyright © 2022, MDPI)

DOI

10.3390/ph15121536

PMID

unavailable

Abstract

Statins are included in the category of high-frequency prescription drugs, and their use is on an upward trend worldwide. In 2012, the FDA issued a warning about possible cognitive adverse drug reactions (ADRs) related to statins, some of which are listed in the Summary of Product Characteristics, but there are still concerns about their potential risk of psychiatric events. The aim of this research was to investigate spontaneous reports containing psychiatric ADRs associated with statins by analyzing the EudraVigilance (EV) database. From January 2004 to July 2021, a total of 8965 ADRs were reported for the Systems Organ Class (SOC) "psychiatric disorders", of which 88.64% were registered for atorvastatin (3659), simvastatin (2326) and rosuvastatin (1962). Out of a total of 7947 individual case safety reports (ICSRs) of the 3 statins mentioned above, in 36.3% (2885) of them, statins were considered the only suspected drug, and in 42% (3338), no other co-administered drugs were mentioned. Moreover, insomnia has been reported in 19.3% (1536) of cases, being the most frequent adverse reaction. A disproportionality analysis of psychiatric ADRs was performed. The Reporting Odds Ratio (ROR) and 95% confidence interval (95% CI) were calculated for simvastatin, atorvastatin and rosuvastatin compared with antiplatelets and antihypertensive drugs. The reporting probability for most ADRs of these statins compared to antiplatelets was higher. The reporting probability for insomnia, nightmares and depression produced by statins compared to antihypertensive drugs was also higher. The results of this analysis augment the existing data about a possible correlation between the administration of statins and the occurrence of psychiatric side effects. © 2022 by the authors.

Language: en

Keywords

adult; human; female; male; aged; insomnia; depression; anxiety; suicide attempt; prescription; antihypertensive agent; hallucination; sleep disorder; hydroxymethylglutaryl coenzyme A reductase inhibitor; drug safety; nightmare; simvastatin; atorvastatin; fluindostatin; mevinolin; postmarketing surveillance; Article; rosuvastatin; antithrombocytic agent; statins; psychiatric disorders; EudraVigilance; pitavastatin; psychiatric complication; psychiatric side effects; safety profile